These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 15371830)
1. DNA image cytometry on biopsies can help the detection of localized Gleason 3+3 prostate cancers. Lorenzato M; Rey D; Durlach A; Bouttens D; Birembaut P; Staerman F J Urol; 2004 Oct; 172(4 Pt 1):1311-3. PubMed ID: 15371830 [TBL] [Abstract][Full Text] [Related]
2. DNA Ploidy as surrogate for biopsy gleason score for preoperative organ versus nonorgan-confined prostate cancer prediction. Isharwal S; Miller MC; Epstein JI; Mangold LA; Humphreys E; Partin AW; Veltri RW Urology; 2009 May; 73(5):1092-7. PubMed ID: 19193410 [TBL] [Abstract][Full Text] [Related]
3. Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen: a report of 454 cases. Sebo TJ; Cheville JC; Riehle DL; Lohse CM; Pankratz VS; Myers RP; Blute ML; Zincke H Cancer; 2001 Jun; 91(11):2196-204. PubMed ID: 11391602 [TBL] [Abstract][Full Text] [Related]
4. DNA ploidy and prostate-specific antigen as prognostic factors in clinically resectable prostate cancer. Badalament RA; O'Toole RV; Young DC; Drago JR Cancer; 1991 Jun; 67(12):3014-23. PubMed ID: 1710533 [TBL] [Abstract][Full Text] [Related]
5. Conventional assessment of needle biopsy specimens is more useful than digital image analysis of proliferation and DNA ploidy in prediction of positive surgical margins at radical prostatectomy. Sengupta S; Cheville JC; Lohse CM; Zincke H; Myers RP; Riehle DL; Pankratz VS; Blute ML; Sebo TJ Urology; 2006 Jul; 68(1):94-8. PubMed ID: 16844452 [TBL] [Abstract][Full Text] [Related]
6. Prediction of pathologic stage and postprostatectomy disease recurrence by DNA ploidy analysis of initial needle biopsy specimens of prostate cancer. Ross JS; Figge H; Bui HX; del Rosario AD; Jennings TA; Rifkin MD; Fisher HA Cancer; 1994 Nov; 74(10):2811-8. PubMed ID: 7954242 [TBL] [Abstract][Full Text] [Related]
7. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range. Haese A; Dworschack RT; Partin AW J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298 [TBL] [Abstract][Full Text] [Related]
8. Prostate cancer detection at low prostate specific antigen. Schröder FH; van der Cruijsen-Koeter I; de Koning HJ; Vis AN; Hoedemaeker RF; Kranse R J Urol; 2000 Mar; 163(3):806-12. PubMed ID: 10687982 [TBL] [Abstract][Full Text] [Related]
9. Near-diploidy: a new prognostic factor for clinically localized prostate cancer treated with external beam radiation therapy. Pollack A; Zagars GK; el-Naggar AK; Gauwitz MD; Terry NH Cancer; 1994 Apr; 73(7):1895-903. PubMed ID: 7511039 [TBL] [Abstract][Full Text] [Related]
10. [The role of the absolute value and "density" of the prostate-specific antigen estimated echographically in the selection of patients to undergo a biopsy in suspected prostatic carcinoma. A comparison between PSA, palpation and echography in 95 patients undergoing echo-guided endorectal prostatic biopsy]. Di Donna A; Bazzocchi M; Guerra UP; Bendini M; De Biasi F; Caminiti F; Delendi M Radiol Med; 1993; 85(1-2):84-9. PubMed ID: 7683136 [TBL] [Abstract][Full Text] [Related]
11. [Early diagnosis of prostate carcinoma with reference to the density of prostate-specific antigen]. Schmid HP; Ravery V; Toublanc M; Boccon-Gibod L Schweiz Med Wochenschr; 1996 Sep; 126(36):1530-5. PubMed ID: 8927956 [TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of prognostic factors in men undergoing radical prostatectomy for adenocarcinoma of the prostate, including DNA ploidy, surgical tumor stage, prostatic specific antigen, Gleason grade, and age. Shockley KF; Maatman TJ; Carothers GC; Warzynski MJ Prostate; 1996 Jul; 29(1):46-50. PubMed ID: 8685055 [TBL] [Abstract][Full Text] [Related]
13. [Is it convenient in a screening programme for prostate tumour to do biopsy in people with PSA between 3 and 3.9 ng/ml?]. Parravicini M; Del Boca C Arch Ital Urol Androl; 2003 Jun; 75(2):99-101. PubMed ID: 12868147 [TBL] [Abstract][Full Text] [Related]
14. Micro-focal prostate cancer: a comparison of biopsy and radical prostatectomy specimen features. Boccon-Gibod LM; Dumonceau O; Toublanc M; Ravery V; Boccon-Gibod LA Eur Urol; 2005 Dec; 48(6):895-9. PubMed ID: 16125298 [TBL] [Abstract][Full Text] [Related]
15. Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 Men. Catalona WJ; Richie JP; Ahmann FR; Hudson MA; Scardino PT; Flanigan RC; DeKernion JB; Ratliff TL; Kavoussi LR; Dalkin BL; Waters WB; MacFarlane MT; Southwick PC J Urol; 2017 Feb; 197(2S):S200-S207. PubMed ID: 28012755 [TBL] [Abstract][Full Text] [Related]
16. [Clinical utility of available diagnostic tests in prostatic carcinoma. Results of 500 biopsies. II. Rectal palpation, PSA, and transrectal echography]. Rodríguez Rodríguez R; Mayayo Dehesa T; Galbis Sanjuan F; Jiménez Cidre M; Burgos Revilla FJ; Gómez dos Santos V; García González R Arch Esp Urol; 1997 May; 50(4):339-45. PubMed ID: 9313042 [TBL] [Abstract][Full Text] [Related]
17. Can Prostate-Specific Antigen Kinetics before Prostate Biopsy Predict the Malignant Potential of Prostate Cancer? Kim SJ; Jeong TY; Yoo DS; Park J; Cho S; Kang SH; Lee SH; Jeon SH; Lee TY; Park SY Yonsei Med J; 2015 Nov; 56(6):1492-6. PubMed ID: 26446628 [TBL] [Abstract][Full Text] [Related]
18. Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density. Blackwell KL; Bostwick DG; Myers RP; Zincke H; Oesterling JE J Urol; 1994 Jun; 151(6):1565-70. PubMed ID: 7514689 [TBL] [Abstract][Full Text] [Related]
19. Nuclear deoxyribonucleic acid ploidy and serum prostate specific antigen in operable prostatic adenocarcinoma. Nativ O; Myers RP; Farrow GM; Therneau TM; Zincke H; Lieber MM J Urol; 1990 Aug; 144(2 Pt 1):303-6. PubMed ID: 1695690 [TBL] [Abstract][Full Text] [Related]
20. Detection rates of nonpalpable prostate cancer in Korean men with prostate-specific antigen levels between 2.5 and 4.0 ng/mL. Kim HS; Jeon SS; Choi JD; Kim W; Han DH; Jeong BC; Seo SI; Lee KS; Lee SW; Lee HM; Choi HY Urology; 2010 Oct; 76(4):919-22. PubMed ID: 20303152 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]